



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 81925

Title: Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06143468

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Spain

Author's Country/Territory: China

Manuscript submission date: 2022-11-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-12-05 00:35

Reviewer performed review: 2022-12-17 10:56

Review time: 12 Days and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Lenvatinib is an oral small molecule inhibitor of multiple receptor tyrosine kinases that was approved for the first-line treatment of patients with unresectable liver cancer. The overall survival with Lenvatinib was longer than that with sorafenib, and the ORR was higher than that of sorafenib in hepatitis B virus background subgroup analysis. Studies have shown that Lenvatinib has a synergistic effect with immune checkpoint inhibitors. In this study, the authors evaluated the efficacy of transarterial chemoembolization and Lenvatinib plus PD-1 inhibitors for patients with unresectable hepatocellular carcinoma. The study is overall well designed and the results are very interesting. The authors discussed the results with updated references. Minor comments: 1. There is a minor language polishing, which should be corrected. 2. Figures and tables should be edited and improved according to the journal's guideline. 3. The PubMed ID should be added to the references.



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 81925

Title: Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06143437

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Lecturer, Researcher

Reviewer's Country/Territory: United Kingdom

Author's Country/Territory: China

Manuscript submission date: 2022-11-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-12-05 00:35

Reviewer performed review: 2022-12-17 10:57

Review time: 12 Days and 10 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is an interesting retrospective study about the efficacy and safety of lenvatinib plus transarterial chemoembolization with or without PD-1 inhibitors in unresectable HCC. The study is well performed and the results are interesting. The conclusion is attractive, and important to the clinicians. The reviewer recommends to accept this study after a minor editing.



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 81925

Title: Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06143355

Position: Peer Reviewer

Academic degree: N/A

Professional title: N/A

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2022-11-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-12-05 00:35

Reviewer performed review: 2022-12-17 10:57

Review time: 12 Days and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The study is designed to evaluate the efficacy and safety of TACE in combination with lenvatinib and PD-1 inhibitors in the treatment of unresectable hepatocellular carcinoma. The methods are described in detail, and the results are interesting. The authors recommend that early combination of PD-1 inhibitors has promising efficacy and manageable toxicity in patients with unresectable hepatocellular carcinoma. Overall, the manuscript is very well written. No specific comments to the authors. An acceptable study. Thank you.